Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-23233-6 http://scihub22266oqcxt.onion/10.1038/s41467-021-23233-6 34021152!8140151!34021152     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 3025 Nephropedia Template TP {{tp|p=34021152|t=2021. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance |pdf=|usr=}}{{34021152}} gab.com Text Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=34021152 #FOAvip Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05-0.88) mid-March, 4.14% (95% CI: 3.31-4.99) mid-April and 4.93% (95% CI: 4.02-5.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infection fatality rate is 0.84% (95% CI: 0.70-1.03) and increases exponentially with age. These results confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remained susceptible to SARS-CoV-2 in May 2020. Our study shows the progression of the first epidemic wave and provides a framework to inform the ongoing public health response as viral transmission continues globally. Twit Text FOAVip Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=34021152 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34021152 #FOAvip English Wikipedia <ref>{{Cite pmid|34021152}}</ref> Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance #MMPMID34021152 Le Vu S; Jones G; Anna F; Rose T; Richard JB; Bernard-Stoecklin S; Goyard S; Demeret C; Helynck O; Escriou N; Gransagne M; Petres S; Robin C; Monnet V; Perrin de Facci L; Ungeheuer MN; Leon L; Guillois Y; Filleul L; Charneau P; Levy-Bruhl D; van der Werf S; Noel H Nat Commun 2021[May]; 12 (1): 3025 PMID34021152show ga Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05-0.88) mid-March, 4.14% (95% CI: 3.31-4.99) mid-April and 4.93% (95% CI: 4.02-5.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infection fatality rate is 0.84% (95% CI: 0.70-1.03) and increases exponentially with age. These results confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remained susceptible to SARS-CoV-2 in May 2020. Our study shows the progression of the first epidemic wave and provides a framework to inform the ongoing public health response as viral transmission continues globally. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Viral/blood/*immunology[MESH] |COVID-19/epidemiology/*immunology/virology[MESH] |Child[MESH] |Child, Preschool[MESH] |Epidemics[MESH] |Female[MESH] |France/epidemiology[MESH] |Humans[MESH] |Infant[MESH] |Infant, Newborn[MESH] |Male[MESH] |Middle Aged[MESH] |Prevalence[MESH] |SARS-CoV-2/*immunology/physiology[MESH] |Seroepidemiologic Studies[MESH]Prevalence of SARS-CoV-2 antibodies in France: results from nationwide(epmc).pdf DeepDyve Pubget Overpricing